The Role of Radical Prostatectomy in High-Risk Localized, Node-Positive and Metastatic Prostate Cancer

References

• Siegel RL , MillerKD, JemalA. Cancer statistics, 2015. CA Cancer J. Clin.65(1), 5–29 (2015).
   PubMed Web of Science ®Google Scholar
• Klotz L . Prostate cancer overdiagnosis and overtreatment. Curr. Opin. Endocrinol. Diabetes Obes.20(3), 204–209 (2013).
   PubMedGoogle Scholar
• Schroder FH , HugossonJ, RoobolMJet al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet384(9959), 2027–2035 (2014).
   PubMed Web of Science ®Google Scholar
• Andriole GL , CrawfordED, GrubbRL3rdet al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J. Natl Cancer Inst.104(2), 125–132 (2012).
   PubMedGoogle Scholar
• Moyer VA , ForceUSPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med.157(2), 120–134 (2012).
   PubMed Web of Science ®Google Scholar
• Drazer MW , HuoD, EggenerSE. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J. Clin. Oncol.33(22), 2416–2423 (2015).
   PubMed Web of Science ®Google Scholar
• Barocas DA , MallinK, GravesAJet al. The effect of the United States Preventive Services Task Force grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the US. J. Urol.194(6), 1587–1593 (2015).
   PubMed Web of Science ®Google Scholar
• Banerji JS , WolffEM, MassmanJD3rd, Odem-DavisK, PorterCR, CormanJM. Prostate needle biopsy outcomes in the era of the U.S. preventive services task force recommendation against PSA-based screening. J. Urol.195(1), 66–73 (2015).
   PubMed Web of Science ®Google Scholar
• Cooperberg MR . High-risk prostate cancer: treat the prostate. Lancet378(9809), 2056–2057 (2011).
   PubMed Web of Science ®Google Scholar
• Mohler JL , KantoffPW, ArmstrongAJet al. Prostate cancer, version 2.2014. J. Natl Compr. Canc. Netw.12(5), 686–718 (2014).
   PubMed Web of Science ®Google Scholar
• Gradishar WJ , AndersonBO, BalassanianRet al. Breast Cancer Version 2.2015. J. Natl Compr. Canc. Netw.13(4), 448–475 (2015).
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd , VenookAP, Bekaii-SaabTet al. Colon cancer, version 3.2014. J. Natl Compr. Canc. Netw.12(7), 1028–1059 (2014).
   PubMed Web of Science ®Google Scholar
• Mason MD , ParulekarWR, SydesMRet al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J. Clin. Oncol.33(19), 2143–2150 (2015).
   PubMed Web of Science ®Google Scholar
• Widmark A , KleppO, SolbergAet al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised Phase III trial. Lancet373(9660), 301–308 (2009).
   PubMed Web of Science ®Google Scholar
• Bill-Axelson A , HolmbergL, GarmoHet al. Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med.370(10), 932–942 (2014).
   PubMed Web of Science ®Google Scholar
• Wilt TJ , BrawerMK, JonesKMet al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med.367(3), 203–213 (2012).
   PubMed Web of Science ®Google Scholar
• Abdollah F , SoodA, SammonJDet al. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur. Urol.68(3), 497–505 (2015).
   PubMed Web of Science ®Google Scholar
• Briganti A , KarnesRJ, GandagliaGet al. Natural history of surgically treated high-risk prostate cancer. Urol. Oncol.33(4), 163.e7–13 (2015).
   PubMed Web of Science ®Google Scholar
• Ploussard G , Masson-LecomteA, BeauvalJBet al. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology78(3), 607–613 (2011).
   PubMed Web of Science ®Google Scholar
• Walz J , JoniauS, ChunFKet al. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int.107(5), 765–770 (2011).
   PubMed Web of Science ®Google Scholar
• Roder MA , BergKD, ChristensenIJ, GruschyL, BrassoK, IversenP. Radical prostatectomy in clinically localized high-risk prostate cancer: outcome of 231 consecutive patients. Scand. J. Urol.47(1), 19–25 (2013).
   PubMed Web of Science ®Google Scholar
• Moltzahn F , KarnesJ, GonteroPet al. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. Prostate Cancer Prostatic Dis.18(1), 31–37 (2015).
   PubMed Web of Science ®Google Scholar
• Miocinovic R , BerglundRK, StephensonAJet al. Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology77(4), 946–950 (2011).
   PubMed Web of Science ®Google Scholar
• Di Benedetto A , SoaresR, DoveyZ, BottS, McgregorRG, EdenCG. Laparoscopic radical prostatectomy for high-risk prostate cancer. BJU Int.115(5), 780–786 (2015).
   PubMed Web of Science ®Google Scholar
• Lee D , ChoiSK, ParkJet al. Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer. Korean J. Urol.56(8), 572–579 (2015).
   PubMedGoogle Scholar
• Ritch CR , YouC, MayATet al. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology83(6), 1309–1315 (2014).
   PubMed Web of Science ®Google Scholar
• Busch J , MagheliA, LevaNet al. Matched comparison of outcomes following open and minimally invasive radical prostatectomy for high-risk patients. World J. Urol.32(6), 1411–1416 (2014).
   PubMed Web of Science ®Google Scholar
• Punnen S , MengMV, CooperbergMR, GreeneKL, CowanJE, CarrollPR. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer?BJU Int.112(4), E314–E320 (2013).
   PubMed Web of Science ®Google Scholar
• Pierorazio PM , MullinsJK, EiflerJBet al. Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate cancer. BJU Int.112(6), 751–757 (2013).
   PubMed Web of Science ®Google Scholar
• Hanks GE , PajakTF, PorterAet al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol.21(21), 3972–3978 (2003).
   PubMed Web of Science ®Google Scholar
• Wiegel T , BartkowiakD, BottkeDet al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10 year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur. Urol.66(2), 243–250 (2014).
   PubMed Web of Science ®Google Scholar
• Boorjian SA , KarnesRJ, ViterboRet al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer117(13), 2883–2891 (2011).
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ , EasthamJA, CroninAMet al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J. Clin. Oncol.28(9), 1508–1513 (2010).
   PubMed Web of Science ®Google Scholar
• Cooperberg MR , VickersAJ, BroeringJM, CarrollPR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer116(22), 5226–5234 (2010).
   PubMed Web of Science ®Google Scholar
• Abdollah F , SunM, ThuretRet al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur. Urol.59(1), 88–95 (2011).
   PubMed Web of Science ®Google Scholar
• Bajammal S , DahmP, ScarperoHM, OrovanW, BhandariM. How to use an article about therapy. J. Urol.180(5), 1904–1911 (2008).
   PubMed Web of Science ®Google Scholar
• D’Amico AV , WhittingtonR, MalkowiczSBet al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA280(11), 969–974 (1998).
   PubMed Web of Science ®Google Scholar
• Yossepowitch O , EggenerSE, BiancoFJJret al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J. Urol.178(2), 493–499; discussion 499 (2007).
   PubMed Web of Science ®Google Scholar
• Clinical trials database: NCT02044172. https://clinicaltrials.gov/ct2/show/NCT02044172.
   Google Scholar
• Pierorazio PM , GorinMA, RossAEet al. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30 year experience. Prostate73(15), 1673–1680 (2013).
   PubMed Web of Science ®Google Scholar
• Daneshmand S , QuekML, SteinJPet al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J. Urol.172(6 Pt 1), 2252–2255 (2004).
   PubMed Web of Science ®Google Scholar
• Messing EM , ManolaJ, YaoJet al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol.7(6), 472–479 (2006).
   PubMed Web of Science ®Google Scholar
• Lin CC , GrayPJ, JemalA, EfstathiouJA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J. Natl Cancer Inst.107(7), pii: djv119 (2015).
   Google Scholar
• James ND , SpearsMR, ClarkeNWet al. Impact of node status and radiotherapy on failure-free survival in patients with newly-diagnosed non-metastatic prostate cancer: data from > 690 patients in the control arm of the STAMPEDE trial. Int. J. Radiat. Oncol.90(1), S13 (2014).
   Google Scholar
• Gakis G , BoorjianSA, BrigantiAet al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur. Urol.66(2), 191–199 (2014).
   PubMed Web of Science ®Google Scholar
• Frohmuller HG , TheissM, ManseckA, WirthMP. Survival and quality of life of patients with stage D1 (T1–3 pN1–2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur. Urol.27(3), 202–206 (1995).
   PubMed Web of Science ®Google Scholar
• Ghavamian R , BergstralhEJ, BluteML, SlezakJ, ZinckeH. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J. Urol.161(4), 1223–1227; discussion 1227–1228 (1999).
   PubMed Web of Science ®Google Scholar
• Grimm MO , KamphausenS, HugenschmidtH, Stephan-OdenthalM, AckermannR, VogeliTA. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur. Urol.41(6), 628–634; discussion 634 (2002).
   PubMed Web of Science ®Google Scholar
• Bader P , BurkhardFC, MarkwalderR, StuderUE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cur?J. Urol.169(3), 849–854 (2003).
   PubMed Web of Science ®Google Scholar
• Seiler R , StuderUE, TschanK, BaderP, BurkhardFC. Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. J. Urol.191(5), 1280–1285 (2014).
   PubMed Web of Science ®Google Scholar
• Engel J , BastianPJ, BaurHet al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur. Urol.57(5), 754–761 (2010).
   PubMedGoogle Scholar
• Steuber T , BudausL, WalzJet al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int.107(11), 1755–1761 (2011).
   PubMed Web of Science ®Google Scholar
• Touijer KA , MazzolaCR, SjobergDD, ScardinoPT, EasthamJA. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur. Urol.65(1), 20–25 (2014).
   PubMed Web of Science ®Google Scholar
• Abdollah F , GandagliaG, SuardiNet al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur. Urol.67(2), 212–219 (2015).
   PubMed Web of Science ®Google Scholar
• Albertsen PC , HanleyJA, BarrowsGHet al. Prostate cancer and the Will Rogers phenomenon. J. Natl Cancer Inst.97(17), 1248–1253 (2005).
   PubMedGoogle Scholar
• Briganti A , KarnesRJ, Da PozzoLFet al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–4 pN+ prostate cancer: results of a matched analysis. Eur. Urol.59(5), 832–840 (2011).
   PubMed Web of Science ®Google Scholar
• Flanigan RC , SalmonSE, BlumensteinBAet al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Kommoss S , RochonJ, HarterPet al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann. Surg. Oncol.17(1), 279–286 (2010).
   PubMed Web of Science ®Google Scholar
• Haslinger M , FrancescuttiV, AttwoodKet al. A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Med.2(3), 334–342 (2013).
   PubMed Web of Science ®Google Scholar
• Kaplan RN , RafiiS, LydenD. Preparing the “soil”: the premetastatic niche. Cancer Res.66(23), 11089–11093 (2006).
   PubMed Web of Science ®Google Scholar
• Fehm T , SagalowskyA, CliffordEet al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin. Cancer. Res.8(7), 2073–2084 (2002).
   PubMed Web of Science ®Google Scholar
• De Bono JS , ScherHI, MontgomeryRBet al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer. Res.14(19), 6302–6309 (2008).
   PubMed Web of Science ®Google Scholar
• Kadmon D , HestonWD, FairWR. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J. Urol.127(6), 1238–1242 (1982).
   PubMed Web of Science ®Google Scholar
• Henry JM , IsaacsJT. Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy. J. Urol.139(5), 1119–1123 (1988).
   PubMed Web of Science ®Google Scholar
• Qin XJ , MaCG, YeDWet al. Tumor cytoreduction results in better response to androgen ablation–a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol. Oncol.30(2), 145–149 (2012).
   PubMed Web of Science ®Google Scholar
• Culp SH , SchellhammerPF, WilliamsMB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur. Urol.65(6), 1058–1066 (2014).
   PubMed Web of Science ®Google Scholar
• Parker CC , SydesMR, MasonMDet al. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int.111(5), 697–699 (2013).
   PubMed Web of Science ®Google Scholar
• Clinical trials database: NCT00268476. https://clinicaltrials.gov/ct2/show/NCT00268476.
   Google Scholar
• Nederlands trial register: NTR271. www.trialregister.nl/trialreg/admin/rctview.asp?TC=271.
   Google Scholar
• Clinical trials database: NCT01957436. https://clinicaltrials.gov/ct2/show/NCT01957436.
   Google Scholar
• Bayne CE , WilliamsSB, CooperbergMRet al. Treatment of the primary tumor in metastatic prostate cancer: current concepts and future perspectives. Eur. Urol. doi: 10.1016/j.eururo.2015.04.036 (2015) ( Epub ahead of print).
   Google Scholar
• Clinical trials database: NCT01751438. https://clinicaltrials.gov/ct2/show/NCT01751438.
   Google Scholar